Ma Yinglong Pharmaceutical Co., Ltd. cooperates with comadico to develop a new class of pratestosterone sulfate sodium tablets

At present, pharmacy, pharmacodynamics, phase I and phase II clinical studies have been completed, and supplementary clinical studies are under way According to the contract, the rights and interests of the project are jointly owned by both parties, with each party accounting for 50% The company needs to carry out follow-up supplementary clinical trials and production verification related technical content on the basis of preliminary clinical research of comadico Ma Yinglong said that the cooperation of the project is conducive to enriching the company's gynecology product line and optimizing the product echelon structure Ma Yinglong Pharmaceutical Group and Beijing kangmadico Co., Ltd held the signing ceremony of national first-class new drug on December 29 The signing ceremony of Ma Yinglong Pharmaceutical Group and Beijing kangmadico Biotechnology Development Co., Ltd on national first-class new drug pratestosterone sulfate sodium tablet was held in the conference room on the fourth floor of the company's technology center Su Guangxiang, vice chairman and general manager of the company, Xia Jun, chief engineer, Yan changkai, general manager of product development center, attended the signing ceremony with Pang Fei, chairman of Beijing kangmadico Biotechnology Development Co., Ltd At the meeting, Mr Su introduced the development and strategic vision of Ma Yinglong Pharmaceutical Group in recent years, analyzed and discussed the market positioning and commercial application of pratestosterone sulfate sodium tablets in the future, and said that he was very optimistic about the market prospect of pratestosterone sulfate sodium tablets Pang Fei, chairman of Beijing kangmadico company, also introduced the application prospect and foreign research results of pratestosterone sulfate sodium tablets The two sides held a signing ceremony in a friendly and warm atmosphere Prasterone sulfate sodium tablet is a kind of national first-class new drug, exclusive variety It has two national invention patents, indication and production technology It is used to treat all kinds of discomfort symptoms caused by vaginal atrophy in postmenopausal women It is a non estrogen therapy, safe and effective in clinical application, and more and more recognized by the world's medical community Prasterone sulfate sodium tablets will become the first choice of physiological therapy in the clinical treatment of women's vaginal atrophy caused by various kinds of discomfort symptoms in the next decades, which will bring good news for hundreds of millions of patients to improve their quality of life and relieve their pain This product has outstanding competitive advantage in the domestic market, with considerable social and economic benefits President Pang and his delegation visited the company's showroom ↑ Figure 2: General Manager Su made an exchange discussion with Beijing kangmadico before signing the contract ↑ Figure 3: both parties held a signing ceremony in a warm and friendly atmosphere ↑ Figure 4: general representative Ma Yinglong signed the contract with Beijing kangmadico on behalf of Ma Yinglong Ma Yinglong is one of the first batch of Chinese time-honored brand enterprises recognized by the Ministry of Commerce It was founded in 1582 A.D and has grown into a professional pharmaceutical listed company after more than 400 years of sustained, rapid and healthy development
Ma Yinglong deepens the implementation of brand management strategy, adheres to the core positioning of the anorectal and lower digestive tract fields, and actively seeks development opportunities around the big health field; implements the idea of "industry focuses on speed, business focuses on quality, diagnosis and treatment focuses on layout", focuses on the core advantage fields, constructs the industrial chain of drug management, diagnosis and treatment technology, and medical service, and realizes the three-dimensional and focused industry superposition About Ma Yinglong pharmaceutical Beijing Kangmai dike Biotechnology Development Co., Ltd was founded in September 1997, its predecessor is Beijing Kangmai Investment Consulting Co., Ltd., which is a joint venture between China and Canada The company changed its name to the current name in February 2001, and changed to a wholly foreign-owned enterprise in June 2008 As a private pharmaceutical technology development enterprise, the company adheres to the tenet of "technology creates wealth and technology innovation serves the people" and adheres to the path of medical innovation serving the public health Over the past decade, through close cooperation with a number of domestic and foreign scientific research institutions, the company has continued to forge ahead in the field of biological medicine and the upgrading of old pharmaceutical products, so as to improve people's lives The demand for quality drugs has made due contributions.